Back to Search Start Over

Deep amplicon sequencing for culture-free prediction of susceptibility or resistance to 13 anti-tuberculous drugs

Authors :
Cyril Gaudin
Stefan Niemann
Alice Ferré
Stéphanie Duthoy
Vanessa Mathys
Yannick Laurent
Emmanuel André
Elisa Tagliani
Bouke C. de Jong
Philip Supply
Andrea M. Cabibbe
Silke Feuerriegel
Caroline Allix-Béguec
Nelly Badalato
Sandy Contreras
Michel K. Kaswa
Leen Rigouts
Agathe Jouet
Daniela Maria Cirillo
Maren Diels
Institute of Tropical Medicine [Antwerp] (ITM)
Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven)
Universiteit Antwerpen [Antwerpen]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 (CIIL)
Institut Pasteur de Lille
Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre National de la Recherche Scientifique (CNRS)
Genoscreen [Lille]
Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)
Forschungszentrum Borstel - Research Center Borstel
German Centre for Infection Research - partner site Hamburg-Lübeck-Borstel-Riems (DZIF)
National Tuberculosis Program [Kinshasa]
IRCCS Ospedale San Raffaele [Milan, Italy]
Maladies bactériennes = Bacterial diseases [Bruxelles]
Sciensano [Bruxelles]
Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur de Lille
Parts of this work have been supported by the European Union PathoNGen-Trace project (FP7-278864) and by the World Health Organization (for the TB drug resistance survey conducted in the Democratic Republic of the Congo). B.C. de Jong and L. Rigouts were supported by European Research Council starting grant 'INTERRUPTB' (grant agreement 311725).
European Project: 278864,EC:FP7:HEALTH,FP7-HEALTH-2011-two-stage,PATHONGEN-TRACE(2012)
European Project: 311725,EC:FP7:ERC,ERC-2012-StG_20111109,INTERRUPTB(2013)
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Universiteit Antwerpen = University of Antwerpen [Antwerpen]
Noel, Anne-Laure
Next Generation Genome Based High Resolution Tracing of Pathogens - PATHONGEN-TRACE - - EC:FP7:HEALTH2012-01-01 - 2016-06-30 - 278864 - VALID
Estimating the effective reproductive rate of M. tuberculosis from changes in molecular clustering rates, to measure the impact of public health interventions on TB transmission - INTERRUPTB - - EC:FP7:ERC2013-01-01 - 2017-12-31 - 311725 - VALID
Source :
European Respiratory Journal, European Respiratory Journal, European Respiratory Society, In press, ⟨10.1183/13993003.02338-2020⟩, The European Respiratory Journal, article-version (VoR) Version of Record, The European respiratory journal, European Respiratory Journal, European Respiratory Society, 2021, 57, pp.2002338. ⟨10.1183/13993003.02338-2020⟩, European Respiratory Journal, 2021, 57, pp.2002338. ⟨10.1183/13993003.02338-2020⟩
Publication Year :
2020

Abstract

Conventional molecular tests for detecting Mycobacterium tuberculosis complex (MTBC) drug resistance on clinical samples cover a limited set of mutations. Whole-genome sequencing (WGS) typically requires culture. Here, we evaluated the Deeplex Myc-TB targeted deep-sequencing assay for prediction of resistance to 13 anti-tuberculous drugs/drug classes, directly applicable on sputum. With MTBC DNA tests, the limit of detection was 100–1000 genome copies for fixed resistance mutations. Deeplex Myc-TB captured in silico 97.1–99.3% of resistance phenotypes correctly predicted by WGS from 3651 MTBC genomes. On 429 isolates, the assay predicted 92.2% of 2369 first- and second-line phenotypes, with a sensitivity of 95.3% and a specificity of 97.4%. 56 out of 69 (81.2%) residual discrepancies with phenotypic results involved pyrazinamide, ethambutol and ethionamide, and low-level rifampicin or isoniazid resistance mutations, all notoriously prone to phenotypic testing variability. Only two out of 91 (2.2%) resistance phenotypes undetected by Deeplex Myc-TB had known resistance-associated mutations by WGS analysis outside Deeplex Myc-TB targets. Phenotype predictions from Deeplex Myc-TB analysis directly on 109 sputa from a Djibouti survey matched those of MTBSeq/PhyResSE/Mykrobe, fed with WGS data from subsequent cultures, with a sensitivity of 93.5/98.5/93.1% and a specificity of 98.5/97.2/95.3%, respectively. Most residual discordances involved gene deletions/indels and 3–12% heteroresistant calls undetected by WGS analysis or natural pyrazinamide resistance of globally rare “Mycobacterium canettii” strains then unreported by Deeplex Myc-TB. On 1494 arduous sputa from a Democratic Republic of the Congo survey, 14 902 out of 19 422 (76.7%) possible susceptible or resistance phenotypes could be predicted culture-free. Deeplex Myc-TB may enable fast, tailored tuberculosis treatment.<br />The novel Deeplex Myc-TB molecular assay shows a high degree of accuracy for extensive prediction of susceptibility and resistance to 13 anti-tuberculous drugs, directly achievable without culture, which may enable fast, tailored tuberculosis treatment https://bit.ly/3bAvcAt

Details

ISSN :
13993003 and 09031936
Volume :
57
Issue :
3
Database :
OpenAIRE
Journal :
The European respiratory journal
Accession number :
edsair.doi.dedup.....0b7809621102ce6836ad5b0de59e323c
Full Text :
https://doi.org/10.1183/13993003.02338-2020⟩